Two deaths linked to the chikungunya vaccine highlight risks of unrepresentative clinical trials

Two deaths linked to the chikungunya vaccine highlight risks of unrepresentative clinical trials

The European Medicines Agency (EMA) has recommended restricting the use of the first vaccine developed against chikungunya — an infectious disease transmitted by mosquitoes in tropical areas that causes, among other symptoms, severe joint pain that lasts for several months or even years — in people aged over 65. The measure comes after at least 17 serious adverse events, two of them fatal, were reported in people over 62 years of age who had received the single dose of Ixchiq, the drug’s brand name.

Seguir leyendo